We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
80 own
51 watching
Current Price
$9.87
$-0.16
(-1.6%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
678.68M
52-Week High
33.86
52-Week Low
9.59
Average Volume
1.61M
Dividend Yield
--
P/E Ratio
--
Market Capitalization678.68M
52-Week High33.86
52-Week Low9.59
Average Volume1.61M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Developing gene editing therapies based on CRISPR/Cas9 technology.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Benzinga
26days ago
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Latest Ratings for ...
Stock Options Channel
2 months ago
Investors in Editas Medicine Inc (EDIT) saw new options begin trading today, for the October 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new October 28th contracts and identified one put and one call contract of particular ...
Globe Newswire
6 months ago
Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling studies CAMBRIDGE, Mass., May 04, 2022...
Ticker Report
7 months ago
Cambridge Investment Research Advisors Inc. lessened its holdings in Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) by 62.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned ...
Zolmax
7 months ago
Cambridge Investment Research Advisors Inc. decreased its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) by 62.8% in the 4th quarter, Holdings Channel reports. The firm owned 65,876 shares of the companys stock after selling 111,405 shares during the period. Cambridge ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$9.87
$-0.16
(-1.6%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00